Reported results
- Cash, cash equivalents and marketable securities were $984.5 million as of September 30, 2026.
- Research and Development (R&D) expenses were $39.2 million for the third quarter of 2026.
- General and Administrative (G&A) expenses were $23.0 million for the third quarter of 2026.
- Net loss was $56.9 million, or $(0.64) per share, for the third quarter of 2026.
- Total revenues were $1.604 million for the third quarter of 2026.
Guidance
- The Company anticipates its existing cash, cash equivalents and marketable securities as of September 30, 2026 will be sufficient to fund operations through 2029.
- PIVOT-006 Phase 3 topline data anticipated November 2026.
- BOND-003 Cohort P and CORE-008 Cohort CX 12-month data anticipated December 2026.
- BLA completion for BCG-unresponsive NMIBC anticipated Q4 2026.
Price and volatility reaction
The stock moved +17.3% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved +3.5 vol points across the event (constant-maturity series — not the front-week crush).
| Measure | Value | Basis |
|---|---|---|
| Close before release | 64.8 | 2026-11-05 |
| Close after release | 75.99 | 2026-11-06 |
| Realised move | +17.3% | close to close |
| 30d ATM IV change | +3.5 vol pts | constant-maturity series, not the front expiry |
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-06 (8-K, Item 2.02). Read the original filing on sec.gov.
